Clinical Trial Update: Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]

View source ↗

Summary

Phase 3 Zephyrus I trial evaluating pamrevlumab for idiopathic pulmonary fibrosis has been terminated, and results have been posted on clinicaltrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Pamrevlumab (pamrevlumab)

Snippet

Sponsor: Kyntra Bio | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2024-09-19